c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules
- PMID: 22233760
- PMCID: PMC3267663
- DOI: 10.1186/1479-5876-10-7
c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules
Abstract
Background: A large amount of information has been collected on the molecular tumorigenesis of thyroid cancer. A low expression of c-KIT gene has been reported during the transformation of normal thyroid epithelium to papillary carcinoma suggesting a possible role of the gene in the differentiation of thyroid tissue rather than in the proliferation. The initial presentation of thyroid carcinoma is through a nodule and the best way nowadays to evaluate it is by fine-needle aspiration (FNA). However many thyroid FNAs are not definitively benign or malignant, yielding an indeterminate or suspicious diagnosis which ranges from 10 to 25% of FNAs. BRAF mutational analysis is commonly used to assess the malignancy of thyroid nodules but unfortunately it still leaves indeterminate diagnoses. The development of molecular initial diagnostic tests for evaluating a thyroid nodule is needed in order to define optimal surgical approach for patients with uncertain diagnosis pre- and intra-operatively.
Methods: In this study we extracted RNA from 82 FNA smears, 46 malignant and 36 benign at the histology, in order to evaluate by quantitative Real Time PCR the expression levels of c-KIT gene.
Results: We have found a highly preferential decrease rather than increase in transcript of c-KIT in malignant thyroid lesions compared to the benign ones. To explore the diagnostic utility of c-KIT expression in thyroid nodules, its expression values were divided in four arbitrarily defined classes, with class I characterized by the complete silencing of the gene. Class I and IV represented the two most informative groups, with 100% of the samples found malignant or benign respectively. The molecular analysis was proven by ROC (receiver operating characteristic) analysis to be highly specific and sensitive improving the cytological diagnostic accuracy of 15%.
Conclusion: We propose the use of BRAF test (after uncertain cytological diagnosis) to assess the malignancy of thyroid nodules at first, then the use of the c-KIT expression to ultimately assess the diagnosis of the nodules that otherwise would remain suspicious. The c-KIT expression-based classification is highly accurate and may provide a tool to overcome the difficulties in today's preoperative diagnosis of thyroid suspicious malignancies.
Figures


Similar articles
-
The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management.BMC Cancer. 2015 Nov 19;15:918. doi: 10.1186/s12885-015-1917-2. BMC Cancer. 2015. PMID: 26581891 Free PMC article.
-
Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?Cytopathology. 2021 Jan;32(1):37-44. doi: 10.1111/cyt.12904. Epub 2020 Oct 12. Cytopathology. 2021. PMID: 32803788
-
The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.J Endocrinol Invest. 2019 Feb;42(2):157-166. doi: 10.1007/s40618-018-0895-z. Epub 2018 Apr 27. J Endocrinol Invest. 2019. PMID: 29704233
-
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.Endocr Pathol. 2020 Mar;31(1):57-66. doi: 10.1007/s12022-019-09596-z. Endocr Pathol. 2020. PMID: 31811566
-
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules.Am J Surg. 2010 Jul;200(1):136-43. doi: 10.1016/j.amjsurg.2009.08.029. Am J Surg. 2010. PMID: 20637346 Free PMC article. Review.
Cited by
-
Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.Oncotarget. 2016 Jul 19;7(29):45776-45788. doi: 10.18632/oncotarget.10166. Oncotarget. 2016. PMID: 27329729 Free PMC article.
-
Thyroid cancer in Ecuador: A genetic variants review and a cross-sectional population-based analysis before and after COVID-19 pandemic.Heliyon. 2023 Dec 21;10(1):e23964. doi: 10.1016/j.heliyon.2023.e23964. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38226262 Free PMC article. Review.
-
The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management.BMC Cancer. 2015 Nov 19;15:918. doi: 10.1186/s12885-015-1917-2. BMC Cancer. 2015. PMID: 26581891 Free PMC article.
-
Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.Tumour Biol. 2016 Jan;37(1):611-8. doi: 10.1007/s13277-015-3837-9. Epub 2015 Aug 4. Tumour Biol. 2016. PMID: 26240026
-
Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid.BMC Genomics. 2015;16 Suppl 1(Suppl 1):S7. doi: 10.1186/1471-2164-16-S1-S7. Epub 2015 Jan 15. BMC Genomics. 2015. PMID: 25923053 Free PMC article.
References
-
- Udelsman R, Chen H. The current management of thyroid cancer. Adv Surg. 1999;33:1–27. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials